BioCryst Pharmaceuticals has secured a $34.7m contract from the US Centers for Disease Control and Prevention (CDC) for the supply of up to 50,000 doses of its approved antiviral influenza therapy, RAPIVAB (peramivir injection) over a five-year period.
10 Sep 2018
06 Sep 2018
Aurobindo Pharma USA has agreed to acquire selected portions of Sandoz US portfolio from Novartis for $900m of cash and $100m of potential earn-outs.
19 Jul 2018
UK-based EUSA Pharma has agreed to acquire the global rights of Sylvant (siltuximab), a rare blood disorder drug, from Janssen Sciences Ireland UC for $115m.
18 Jul 2018
Clinigen Group has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Novartis.
11 Jul 2018
Takeda Pharmaceutical’s £45.3bn ($62bn) acquisition of Shire has been unconditionally approved by the US Federal Trade Commission (FTC).